110 related articles for article (PubMed ID: 3713640)
1. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study.
Panettiere FJ; Jones SE; Oishi N; Eyre HJ; O'Bryan RM; Andes WA; Taylor SA; Grozea PN
Med Pediatr Oncol; 1986; 14(2):78-80. PubMed ID: 3713640
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
4. Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer. A cancer and leukemia group B study.
Forastiere AA; Perry MC; Hughes AK; Wood WC
Cancer Chemother Pharmacol; 1984; 13(3):226-9. PubMed ID: 6488443
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.
Miller TP; Jones SE; Alberts DS; Mackel C
Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA
Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
[No Abstract] [Full Text] [Related]
10. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
11. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
Haim N; Epelbaum R; Cohen Y; Robinson E
Cancer; 1984 Nov; 54(9):1999-2002. PubMed ID: 6548173
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced non-small cell lung cancer with bisantrene.
Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
[No Abstract] [Full Text] [Related]
13. Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study.
Bukowski RM; Theodors A; Purvis JD; Budd GT; Weick JK; Gahbauer R
Am J Clin Oncol; 1987 Oct; 10(5):376-9. PubMed ID: 3661488
[TBL] [Abstract][Full Text] [Related]
14. Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
Panettiere FJ; Haas C; McDonald B; Costanzi JJ; Talley RW; Athens J; Oishi N; Heilbrun LK; Chen TT
J Clin Oncol; 1984 May; 2(5):420-4. PubMed ID: 6427416
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of bisantrene in non-small cell lung cancer.
Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
[TBL] [Abstract][Full Text] [Related]
17. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.
MacDonald JS; Woolley PV; Smythe T; Ueno W; Hoth D; Schein PS
Cancer; 1979 Jul; 44(1):42-7. PubMed ID: 455263
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of bisantrene in patients with advanced non-small cell lung carcinoma.
Feld R; Evans WK; Shepherd FA; Deboer G; Ottema B
Cancer Treat Rep; 1985 Feb; 69(2):209-10. PubMed ID: 3971392
[TBL] [Abstract][Full Text] [Related]
19. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
Douglass HO; Lavin PT; Goudsmit A; Klaassen DJ; Paul AR
J Clin Oncol; 1984 Dec; 2(12):1372-81. PubMed ID: 6439836
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM).
Bitran JD; Desser RK; Kozloff MF; Billings AA; Shapiro CM
Cancer Treat Rep; 1979; 63(11-12):2049-51. PubMed ID: 393388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
